Palmitoylation of solute carriers

Villanueva, Cecilia E.; Hagenbuch, Bruno

doi:10.1016/j.bcp.2023.115695

Cited by 3 publications

(1 citation statement)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The common types of PTMs include ubiquitination ( 13 ), acetylation ( 14 , 15 ), phosphorylation ( 16 ), methylation ( 17 ), glycosylation ( 18 , 19 ), SUMOylation ( 20 ), prenylation ( 21 ), GlcNAcylation ( 18 ), succinylation ( 22 ), palmitoylation ( 23 ), and neddylation ( 24 , 25 ). Ubiquitination is one common type of PTMs, in which a target protein is added a small protein called ubiquitin or multiple ubiquitins, leading to protein degradation by the proteasome ( 26 ).…”

Section: Introductionmentioning

confidence: 99%

PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy

Ren,

Wang,

Liu

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapy has been developed, which harnesses and enhances the innate powers of the immune system to fight disease, particularly cancer. PD-1 (programmed death-1) and PD-L1 (programmed death ligand-1) are key components in the regulation of the immune system, particularly in the context of cancer immunotherapy. PD-1 and PD-L1 are regulated by PTMs, including phosphorylation, ubiquitination, deubiquitination, acetylation, palmitoylation and glycosylation. PROTACs (Proteolysis Targeting Chimeras) are a type of new drug design technology. They are specifically engineered molecules that target specific proteins within a cell for degradation. PROTACs have been designed and demonstrated their inhibitory activity against the PD-1/PD-L1 pathway, and showed their ability to degrade PD-1/PD-L1 proteins. In this review, we describe how PROTACs target PD-1 and PD-L1 proteins to improve the efficacy of immunotherapy. PROTACs could be a novel strategy to combine with radiotherapy, chemotherapy and immunotherapy for cancer patients.

show abstract